3-(5-甲基-1H-吡唑-1-基)丙酸 | 180741-46-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(5-甲基-1H-吡唑-1-基)丙酸
• 中文别名: 3-(5-甲基-1-吡唑基)丙酸
• 英文名称: 3-(5-methyl-1H-pyrazol-1-yl)propanoic acid
• 英文别名: 3-(5-methylpyrazol-1-yl)propanoic acid
• CAS: 180741-46-2
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD00996156
• 分子量: 154.17
• InChiKey: AVWPEIKOPXXROD-UHFFFAOYSA-N

物化性质

• 沸点：
  317.5±25.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)
• 溶解度：
  6.9 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933199090

文献信息

• MCL-1 INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20190352271A1

  公开（公告）日：2019-11-21

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开涉及通常用于治疗癌症的化合物和药物组合物。
• [EN] INHIBITORS OF APOL1 AND USE OF THE SAME<br/>[FR] INHIBITEURS D'APOL1 ET LEUR UTILISATION
  申请人：VERTEX PHARMA

  公开号：WO2021252849A1

  公开（公告）日：2021-12-16

  The disclosure provides compounds of Formula (I), deuterated derivatives of those compounds, and pharmaceutically acceptable salts of those compounds and derivatives, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

  该披露提供了式（I）的化合物，这些化合物的氘代衍生物，以及这些化合物和衍生物的药用盐，包含这些化合物的组合物，以及使用这些化合物的方法，包括用于治疗APOL1介导的肾病。
• MCL-1 inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10703733B2

  公开（公告）日：2020-07-07

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开内容一般涉及可用于治疗癌症方法的化合物和药物组合物。
• [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
  申请人：Neurocrine Biosciences, Inc.

  公开号：US11053242B2

  公开（公告）日：2021-07-06

  Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: wherein R1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.

  具有式 (I) 结构的化合物，包括立体异构体及其药学上可接受的盐和溶液： 其中 R1 如本文所定义。这类化合物是囊泡单胺转运体 2（VMAT2）的抑制剂，可用于治疗过度运动障碍等疾病。还公开了含有这些化合物的组合物与药学上可接受的载体或稀释剂的组合物，以及有关在有需要的受试者中使用的方法。
• [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO
  申请人：Neurocrine Biosciences, Inc.

  公开号：US20160289226A1

  公开（公告）日：2016-10-06

  Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: wherein R 1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.